Top Stories
The tool could help identify which patients are most likely to benefit from immunotherapy and stem cell transplantation.
The green light comes after the US regulator initially rejected the hepatitis delta virus (HDV) drug about four years ago.
Anti-ageing startup Retro Biosciences closed its next round of funding at a valuation of $1.8 billion, while CVC Capital Partners and Groupe Bruxelles Lambert launched a €10.7 billion cash bid for Recordati.
The combination of neoepitope-based cancer vaccine Tedopi plus Keytruda significantly improved PFS compared to best supportive care in Phase II testing.
The EMA's Committee for Medicinal Products for Human Use backed clearance of camizestrant based on progression-free survival data from the Phase III SERENA-6 study.
Conference News
22-May-2026 at 3:55 PM EDT, by University of Chicago Medical Center contact patient servicesPhysicians, scientists, and trainees from the University of Chicago Medicine Comprehensive Cancer Center (UC...
The 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be grandly held from May 29 to June 2 in Chicago, United States. As the most influential academic event in the global o...
EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl) in early liver cancerPhase III data from SERENA-6, DESTINY-Breast09 and TROPION-Brea...
BOSTON--(BUSINESS WIRE)-- Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced it will showcase data across its portfolio of high-quality comprehensive geno...
MORRISVILLE, N.C.--(BUSINESS WIRE)-- SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collabora...
